LAUSR

This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents. Recent trends have shown an increasing burden of atherosclerotic cardiovascular disease (ASCVD) and cardiovascular mortality that are paralleled by a rising prevalence of obesity and type 2 diabetes mellitus.1 Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have protective cardiovascular effects as shown in recent trials.2 However, few studies have examined the determinants of SGLT-2i use in a contemporary cohort of patients with ASCVD and diabetes mellitus.